Omeros

Omeros defends its drug, but still won’t answer basic questions
Omeros defends its drug, but still won’t answer basic questions
Stat
Omeros
OMS721
Flag link:
These 3 Biotech Stocks Have Doubled This Year; Can They Keep Climbing?
These 3 Biotech Stocks Have Doubled This Year; Can They Keep Climbing?
Motley Fool
biotech
Omeros
Cara Therapeutics
Portola Pharmaceuticals
Flag link:
Biotech Movers: OncoMed, Incyte, Omeros
Biotech Movers: OncoMed, Incyte, Omeros
TheStreet.com
biotech
OncoMed
tarextumab
small cell lung cancer
Incyte
Eli Lilly
baricitinib
Omeros
Flag link:
Omeros Kidney Drug Reports Good Results
Omeros Kidney Drug Reports Good Results
Investopedia
Omeros
OMS721
kidney disease
Flag link:
Omeros' Pipeline Is Largely Neglected
Omeros' Pipeline Is Largely Neglected
Seeking Alpha
Omeros
OMS824
OMS721
Qmidria
Flag link:
FDA fast-tracks Omeros' kidney drug as company moves into Phase 3 tests
FDA fast-tracks Omeros' kidney drug as company moves into Phase 3 tests
Bizjournals.com
FDA
fast track
Omeros
OMS721
kidney disease
Flag link:
Omeros notches $13 million in sales of first drug
Omeros notches $13 million in sales of first drug
Bizjournals.com
Omeros
Omidria
post-surgical pain
Flag link:
Omeros CEO: For biotechs, better to be a jack of all trades than a master of one
Omeros CEO: For biotechs, better to be a jack of all trades than a master of one
Bizjournals.com
Omeros
Flag link:
What Lit a Fire Under These 3 Pharma Stocks
What Lit a Fire Under These 3 Pharma Stocks
24/7 Wall St
Aveo Pharmaceuticals
Omeros
Corbus Pharmaceuticals
Flag link:
Omeros Corporation: Another Biotech Bubble In The Making?
Omeros Corporation: Another Biotech Bubble In The Making?
Yahoo/Benzinga
Omeros
OMS721
Soliris
aHUS
Flag link:
Omeros reports 4Q loss
Omeros reports 4Q loss
Yahoo/AP
Omeros
earnings
Flag link:
Omeros suspends OMS824 trial in Huntington's Disease
Omeros suspends OMS824 trial in Huntington's Disease
Seeking Alpha
Omeros
OMS824
Huntington's disease
Flag link:
FDA approves Omeros eye drug
FDA approves Omeros eye drug
Yahoo/Reuters
FDA
Omeros
Omidria
cataracts
Flag link:
2nd Half Of 2014 Biotechnology Catalysts: Part 1
2nd Half Of 2014 Biotechnology Catalysts: Part 1
Seeking Alpha
AcelRx
Anacor
BioDelivery Sciences
Eagle Pharmaceuticals
MannKind
Navidea Biopharmaceuticals
Orexigen
Omeros
EnteroMedics
Progenics
Trimel Pharmaceuticals
Flag link:
Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.
Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.
Motley Fool
Medicines Company
Omeros
OPKO Health
Vivus
OMS721
Qsymia
Fibrocaps
Flag link:
Today's Biggest Biotech Stories: Dendreon, AbbVie, and Omeros
Today's Biggest Biotech Stories: Dendreon, AbbVie, and Omeros
Motley Fool
Dendreon
AbbVie
Omeros
Provenge
prostate cancer
ABT-450
hepatitis C
OMS721
Flag link:
3 Under-the-Radar Biotech Stocks You Need to Watch in 2014
3 Under-the-Radar Biotech Stocks You Need to Watch in 2014
Motley Fool
Nektar
Omeros
Spectrum Pharmaceuticals
Flag link:
Omeros Corp reports additional positive phase 1 clinical data for Oms824 for the treatment of cognitive disorders
Omeros Corp reports additional positive phase 1 clinical data for Oms824 for the treatment of cognitive disorders
Reuters
Omeros
OMS824
cognitive disorders
Flag link:
Positive Data on Omeros' OMS824
Positive Data on Omeros' OMS824
Yahoo/Zacks.com
Omeros
OMS824
schizophrenia
Flag link:
2014 FDA Drug Approval Decision Calendar
2014 FDA Drug Approval Decision Calendar
TheStreet.com
FDA
drug approvals
GSK
Gilead
Theravance
Auxilium
Amarin
Bristol-Myers Squibb
Biogen Idec
Pozen
Vanda
Chelsea Therapeutics
pSivida
Alimera
United Therapeutics
Biomarin
JNJ
Pharmacyclics
Celgene
MannKind
Santarus
AstraZeneca
Durata Therapeutics
Eli Lilly
Omeros
BioDelivery Sciences
Anacor
Keryx
Cubist Pharmaceuticals
Nektar
Flag link: